title: Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
abstract: BACKGROUND
  Because of its outstanding sensitivity, stimulation of calcitonin secretion with iv injection of pentagastrin is widely used for biochemical diagnosis of medullary thyroid cancer.
  
  
  OBJECTIVE
  The objective of this study was to explore the relationship between the results of the pentagastrin stimulation test and extent of disease in patients with previously untreated medullary thyroid cancer.
  
  
  METHODS
  This was a retrospective study.
  
  
  METHODS
  The investigation took place at a tertiary referral center.
  
  
  METHODS
  Included were 89 patients with increased basal calcitonin levels who had a pentagastrin test at this institution before initial neck surgery for medullary thyroid cancer.
  
  
  METHODS
  Measurements included basal and stimulated calcitonin levels, carcinoembryonic antigen levels, primary tumor diameter, extrathyroidal extension, lymph node metastases, and distant metastases.
  
  
  RESULTS
  There was a strong dose-dependent relationship between a less than 10-fold increase in preoperative calcitonin levels after iv stimulation with pentagastrin and both the frequency (41-54 vs. 4-27%; P = 0.001) and number (means of 3.0-10.8 vs. 0-1.1 positive nodes, P < 0.001) of lymph node metastases. Weaker associations were identified with the respective frequency of extrathyroidal extension (14-27 vs. 0-7%; P = 0.027), distant metastasis (9-23 vs. 0%; P = 0.017), and postoperative normalization of calcitonin (40-55 vs. 53-82%; P = 0.029). On multivariate analysis, only lymph node metastases were associated with a less than 10-fold increase in preoperative calcitonin levels.
  
  
  CONCLUSIONS
  Based on these clinical data and preclinical literature, reduced responsiveness to stimulation with pentagastrin may reflect early dedifferentiation. Evidence of this condition may enable early risk stratification in patients with medullary thyroid cancer.
authors: Department of General, Visceral, and Vascular Surgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Strasse 40, Halle (Saale), Germany. andreasmachens@aol.com
authors: Andreas
authors: A
authors: Machens
authors: Steffen
authors: S
authors: Hauptmann
authors: Henning
authors: H
authors: Dralle
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D002116:Calcitonin / Q000097:blood / Q000378:metabolism; D018276:Carcinoma, Medullary / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D003940:Diagnostic Techniques, Endocrine; D042241:Early Diagnosis; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010418:Pentagastrin / Q000494:pharmacology*; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D005765:Gastrointestinal Agents; D002116:Calcitonin; D010418:Pentagastrin